SUMERTA MANCHANDANI: Open Payments
NPI 1649613902 · FAIRFAX, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$624 in 19 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $624
Food & beverage: $446Education: $178
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 3 | $206 |
| E.R. Squibb & Sons, L.L.C. | 1 | $122 |
| Alkermes, Inc. | 6 | $115 |
| Neurocrine BioSciences, Inc. | 4 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $63 |
| Lundbeck LLC | 1 | $19 |
| Janssen Pharmaceuticals, Inc | 1 | $17 |
Products named: COBENFY, ARISTADA, INGREZZA, REXULTI, ABILIFY ASIMTUFII, UZEDY, INVEGA SUSTENNA.
Industry payments across VA — which companies pay providers there.
